LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Hutchison China MediTech Ltd ADR

Fechado

SetorSaúde

15.99 -0.44

Visão Geral

Variação de preço das ações

24h

Atual

Mín

15.82

Máximo

16.05

Indicadores-chave

By Trading Economics

Rendimento

6M

Vendas

162M

P/E

Médio do Setor

5.664

35.733

EPS

0.52

Margem de lucro

3.676

Funcionários

1,780

EBITDA

-5M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+56.54% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

2.6B

Abertura anterior

16.43

Fecho anterior

15.99

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de set. de 2025, 23:59 UTC

Aquisições, Fusões, Aquisições de Empresas

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 de set. de 2025, 22:02 UTC

Grandes Movimentos do Mercado

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 de set. de 2025, 17:01 UTC

Grandes Movimentos do Mercado

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 de set. de 2025, 17:01 UTC

Grandes Movimentos do Mercado

Tron Shares Rise After New Investment From Bravemorning

8 de set. de 2025, 16:14 UTC

Grandes Movimentos do Mercado

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 de set. de 2025, 16:13 UTC

Grandes Movimentos do Mercado

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 de set. de 2025, 23:12 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 de set. de 2025, 23:12 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de set. de 2025, 23:12 UTC

Conversa de Mercado

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 de set. de 2025, 22:56 UTC

Conversa de Mercado

Worst May Be Over for New Zealand Retailers -- Market Talk

8 de set. de 2025, 22:23 UTC

Conversa de Mercado

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 de set. de 2025, 21:51 UTC

Conversa de Mercado

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 de set. de 2025, 21:47 UTC

Grandes Movimentos do Mercado

Microsoft Signs $17.4B AI Deal With Nebius

8 de set. de 2025, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 de set. de 2025, 21:20 UTC

Aquisições, Fusões, Aquisições de Empresas

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 de set. de 2025, 21:19 UTC

Aquisições, Fusões, Aquisições de Empresas

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 de set. de 2025, 21:18 UTC

Aquisições, Fusões, Aquisições de Empresas

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 de set. de 2025, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

8 de set. de 2025, 19:33 UTC

Conversa de Mercado

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 de set. de 2025, 19:22 UTC

Conversa de Mercado

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 de set. de 2025, 19:02 UTC

Conversa de Mercado

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 de set. de 2025, 18:24 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 de set. de 2025, 18:24 UTC

Conversa de Mercado

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 de set. de 2025, 17:29 UTC

Conversa de Mercado

Mexican Inflation Seen Little Changed in August -- Market Talk

8 de set. de 2025, 16:59 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 de set. de 2025, 16:36 UTC

Conversa de Mercado

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 de set. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 de set. de 2025, 16:16 UTC

Ganhos

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 de set. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

8 de set. de 2025, 16:04 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

Comparação entre Pares

Variação de preço

Hutchison China MediTech Ltd ADR Previsão

Preço-alvo

By TipRanks

56.54% parte superior

Previsão para 12 meses

Média 25 USD  56.54%

Máximo 25 USD

Mínimo 25 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

1

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

14.24 / 14.78Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat